Repligen Stock Alpha and Beta Analysis
| RGEN Stock | USD 139.66 10.57 7.04% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Repligen. It also helps investors analyze the systematic and unsystematic risks associated with investing in Repligen over a specified time horizon. Remember, high Repligen's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Repligen's market risk premium analysis include:
Beta 0.13 | Alpha 0.0226 | Risk 2.3 | Sharpe Ratio (0) | Expected Return (0.01) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Repligen Analysis, Repligen Valuation, Repligen Correlation, Repligen Hype Analysis, Repligen Volatility, Repligen Price History and analyze Repligen Performance. Repligen Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Repligen market risk premium is the additional return an investor will receive from holding Repligen long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Repligen. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Repligen's performance over market.| α | 0.02 | β | 0.13 |
Repligen expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Repligen's Buy-and-hold return. Our buy-and-hold chart shows how Repligen performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Repligen Market Price Analysis
Market price analysis indicators help investors to evaluate how Repligen stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Repligen shares will generate the highest return on investment. By understating and applying Repligen stock market price indicators, traders can identify Repligen position entry and exit signals to maximize returns.
Repligen Return and Market Media
The median price of Repligen for the period between Fri, Nov 7, 2025 and Thu, Feb 5, 2026 is 162.33 with a coefficient of variation of 4.94. The daily time series for the period is distributed with a sample standard deviation of 7.91, arithmetic mean of 160.06, and mean deviation of 6.67. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Microcarriers Market Size Grows at 11.48 percent CAGR by 2034, reports Towards Healthcare | 11/17/2025 |
2 | Disposition of 2191 shares by James Bylund of Repligen at 151.21 subject to Rule 16b-3 | 11/18/2025 |
3 | Disposition of 2000 shares by Anthony Hunt of Repligen subject to Rule 16b-3 | 12/04/2025 |
4 | Repligen Assessing Valuation After Coverage Flags Weaker Organic Growth and Margin Pressure | 12/12/2025 |
5 | Insider Trading | 12/31/2025 |
6 | Pacer Advisors Inc. Has 1.37 Million Position in Repligen Corporation RGEN - MarketBeat | 01/02/2026 |
7 | Repligen Executive Chair Tony Hunt to Retire Dr. Martin D. Madaus Elected Chair | 01/06/2026 |
8 | Neogen Hits 10-Month High on Earnings, Upbeat Outlook | 01/09/2026 |
9 | Acquisition by Douglass Brian Robb of 2143 shares of Repligen at 163.86 subject to Rule 16b-3 | 01/12/2026 |
10 | Why Repligen Shares Are Sliding Today | 01/14/2026 |
11 | UBS raises Repligen stock price target to 200 on bioprocessing recovery - Investing.com Nigeria | 01/16/2026 |
12 | UBS Tags Repligen as Bioprocessing Leader for 2026, Cites 20 percent Order Growth and Reshoring Tailwinds | 01/23/2026 |
13 | Thrivent Financial for Lutherans Increases Stock Holdings in Repligen Corporation RGEN - MarketBeat | 02/02/2026 |
About Repligen Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Repligen or other stocks. Alpha measures the amount that position in Repligen has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 71.67 | 77.16 | 69.44 | 46.5 | PTB Ratio | 5.1 | 4.08 | 3.67 | 2.9 |
Repligen Upcoming Company Events
As portrayed in its financial statements, the presentation of Repligen's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Repligen's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Repligen's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Repligen. Please utilize our Beneish M Score to check the likelihood of Repligen's management manipulating its earnings.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Repligen
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Repligen Analysis, Repligen Valuation, Repligen Correlation, Repligen Hype Analysis, Repligen Volatility, Repligen Price History and analyze Repligen Performance. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Repligen technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.